Tag Archives: $1.2

Catalent to buy Paragon Bioservices for $1.2 billion: WSJ

(Reuters) – Drug developer Catalent Inc has agreed to buy privately held, gene-therapy focused Paragon Bioservices Inc for $ 1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter. An all-cash deal between the companies is expected to be announced on Monday morning and would help Catalent expand its capabilities… Read More »

Category: Uncategorized